Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 2398 |
| INN | Onartuzumab |
| Status | Terminated |
| Drug code(s) | PRO143966, RG3638, RO5490258 |
| Brand name | MetMAb |
| mAb sequence source | mAb humanized |
| General Molecular Category | Naked monospecific |
| Format, general category | Fragment-Fc |
| Format details | Fab-Fc |
| Isotype (Fc) | IgG1 |
| Light chain isotype | kappa |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | None |
| Target(s) | cMET |
| Indications of clinical studies | Non-Small Cell Lung Cancer, Glioblastoma, Gastric Cancer, Colorectal Cancer, Breast Cancer |
| Primary therapeutic area | Cancer |
| Most advanced stage of development (global) | Terminated at Phase 3 |
| Status | Inactive |
| Start of clinical phase (IND filing or first Phase 1) | February 15, 2007 |
| Start of Phase 2 | April 15, 2009 |
| Start of Phase 3 | July 15, 2011 |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | Genentech |
| Licensee/Partner | None |
| Comments about company or candidate | NCT02488330 Phase 3 extension study in solid tumors active not recruiting as of July 2016. Two Phase 3 (NCT01887886 and NCT02031744) studies in NSCLC still recruiting as of April 8, 2015. Study in triple negative breast cancer terminated in July 2013; Phase 3 study in NSC lung cancer terminated for lack of clinically meaningful efficacy in March 2014. Removed from Roche pipeline for liver cancer (Phase 1), colorectal cancer (Phase 2) and gastric cancer (Phase 3) as of pipeline update July 24, 2014. |
| Full address of company | South San Francisco, California, United States North America United States of America https://www.gene.com/contact-us/visit-us |
Monovalent; target cMet (aka hepatocyte growth factor receptor)
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |